Toronto, Canada — October 24, 2025 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) has provided a shareholder update, highlighting advancements in its cardiac diagnostic solutions and expressing appreciation for ongoing support.
The company’s team has been focused on building a foundation for commercializing VMS+™ and advancing the company towards growth. Management is pursuing capital to execute the updated business plan and budget.
Ventripoint is working to evolve the user base of VMS+™ from research applications to routine clinical adoption following regulatory clearance/approval of the latest version. Upgrading existing sites to VMS+™ V4 is a priority to ensure users benefit from system improvements and a consistent user experience.
The company continues to position itself as a market leader for congenital heart defects, while increasing awareness of the system’s applicability to additional indications requiring RV measurements and more accurate measurement of all four heart chambers.
Ventripoint plans to update the evidence base with current validation and real-world evidence demonstrating the clinical and financial benefits of the system.
The company is expanding its commercial team to drive sales and growth and has identified experienced candidates on a consulting basis, with plans to transition them to full-time roles as capital is raised.
The marketing function has evolved to characterize market need before committing capital to new product development and to better align sales and marketing resources.
A Device-as-a-Service (DaaS) subscription model has been introduced to reduce friction in the sales cycle and create recurring revenue.
The company is developing new approaches to demonstrations and support in Europe and the U.K. AngioPro, its European distributor, has recommitted to working with Ventripoint and invested in the company.
Ventripoint is collaborating with ASCEND Cardiovascular to create a license agreement for the integration of VMS+™ 3D capabilities into the Ascend technology stack.
The company is working with the Ollie Hinkle Heart Foundation (OHHF) to introduce potential customers and supporters.
Lishman Global has purchased components to manufacture 10 integrated systems for development, demonstration, and regulatory purposes in China.
Ventripoint continues to engage with an India-based family office to pursue distribution, joint ventures, manufacturing, and financial opportunities in South Asia.
The production process for the new magnet-free sensors has been upgraded, and an order has been placed for components to build 25 VMS+™ systems.
The company is working with investment bankers to secure capital and marketing groups to increase awareness and is evaluating strategic non-dilutive funding opportunities.
The company has set strategic priorities focused on achieving commercial traction, supporting clinical innovation, developing compelling ROI models, enhancing platform capabilities, and pursuing strategic collaborations.
Ventripoint invites shareholders to a videoconference on October 30th, 2025, at 1 pm EST.
Hugh MacNaught, President and CEO, hmacnaught@ventripoint.com, (604) 671-4201
Source: Ventripoint Diagnostics Ltd.
